top of page
BIOPER
A MULTICENTER, INTERNATIONAL, NON-CONTROLLED, PHASE II TRIAL TO IDENTIFY THE MOLECULAR MECHANISMS OF RESISTANCE AND SENSITIVITY TO PALBOCICLIB RE-CHALLENGE UPON PROGRESSION TO A PALBOCICLIB COMBINATION IN ER-POSITIVE METASTATIC BREAST CANCER PATIENTS (BIOPER)
CLINICAL TRIAL DETAILS
THIS IS AN OPEN-LABEL CLINICAL TRIAL WITH TWO DIFFERENT PRIMARY OBJECTIVES: A BIOLOGICAL AND A CLINICAL OBJECTIVE. FROM A CLINICAL POINT OF VIEW, THE OBJECTIVE IS TO ASSESS THE CLINICAL BENEFIT OF THE COMBINATION OF PALBOCICLIB AND HORMONOTHERAPY IN PATIENTS WITH ADVANCE BREAST CANCER THAT HAD PREVIOUSLY RECEIVED ENDOCRINE THERAPY IN COMBINATION WITH PALBOCICLIB AND HAD ACHIEVED CLINICAL BENEFIT DURING PALBOCICLIB TREATMENT WITH SUBSEQUENT DISEASE PROGRESSION. FROM A BIOLOGICAL POINT OF VIEW, THE CHALLENGE IS TO DEFINE A MOLECULAR PROFILE THAT ALLOW IDENTIFYING PATIENTS THAT COULD BENEFIT MORE FROM CONTINUING ON PALBOCICLIB AFTER PROGRESSION ON A PRIOR PALBOCICLIB-CONTAINING REGIMEN.
COUNTRY
STATUS
TUMOR TYPE
PHASE
N
SITES
BREAST
21
33
II
Spain, Italy
Closing
TRIAL OVERVIEW
PRESS RELEASE
------
SCIENTIFIC IMPACT
BLOG ARTICLES RELATED
Interview with Dr. Llombart on OncologyTube on the PARSIFAL and BIOPER studies presented at SABCS
Results of our BIOPER study were presented at SABCS 2020
SABCS 2020: Final results of PARSIFAL and BIOPER clinical trials to be presented
100% Recruitment Achieved of BioPER study!
TRIAL SITES
Hospital del Mar (Spain)
Institut Català d' Oncologia Badalona (ICO) (Spain)
Hospital Universitario Doce de Octubre (Spain)
Hospital Clínico San Carlos (Spain)
Hospital Universitario La Paz (Spain)
Hospital Clínico Universitario de Valencia (Spain)
Hospital Universitari i Politècnic La Fe (Spain)
Complejo Hospitalario Universitario de Santiago (CHUS) (Spain)
Complejo Hospitalario Universitario A Coruña (CHUAC) (Spain)
Hospital Universitario Virgen del Rocío (Spain)
Hospital Universitario de León (Spain)
Hospital Universitario Reina Sofía (Spain)
Hospital Universitario Miguel Servet (Spain)
Hospital Universitari Vall D'Hebron (Spain)
Hospital Universitari Sant Joan de Reus (Spain)
Instituto Valenciano de Oncología (IVO) (Spain)
CHU de Besançon (Spain listed on site but likely France)
Institut Català d' Oncologia L'Hospitalet (ICO) (Spain)
Ospedale Antonio Perrino (Italy)
Azienda Sanitaria Universitaria Integrata di Udine (Italy)
Instituto Europeo di Oncologia (Italy)
Dr. Cortes and Dr. Llombart PHERain interview
Beyond Chemotherapy
Dr. Vanes Quiroga
Dr. Sofia Braga
Dr. Silvi Antolín
Dr. Escrivá de Romaní
Dr. Philipp Aftimos
Dr. Manuel Ruiz
Prof. Daniele Generali PHEGain interview
Dr. Jacques Medioni
Dr. Dunca Wheatley
bottom of page